Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), and proprietary biomarkers to optimize clinical treatments. Aclarion’s technology addresses the $134.5B U.S. low back and neck pain market, which according to a 2020 JAMA (Journal of the American Medical Association) article is now the most costly healthcare condition in the United States. The Company is currently utilizing Artificial Intelligence (“AI”) to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. The use of AI in this application is early in its development cycle and is expected to evolve with further research and development. The Company is capturing in databases both the raw spectroscopy data and the post-processed spectral data from every Nociscan completed in order to utilize this data as future training data to teach a machine learning algorithms to associate MRS data with clinical outcomes. The use of AI in this application is aspirational and we intend this type of AI research and development to be an ongoing process applied not only to the various treatment paths associated with back pain, such as conservative therapies, regenerative and cell therapies and surgical intervention, but also to potentially expand into other clinical explorations involving the diagnosis of brain, breast and prostate tumors.
Company profile
Ticker
ACON
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Nocimed, Inc.
SEC CIK
ACON stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Entry into a Material Definitive Agreement
27 Feb 24
424B4
Prospectus supplement with pricing info
27 Feb 24
EFFECT
Notice of effectiveness
27 Feb 24
S-1/A
IPO registration (amended)
23 Feb 24
8-K
Index to Financial Statements
21 Feb 24
S-1/A
IPO registration (amended)
21 Feb 24
S-1/A
IPO registration (amended)
6 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
Latest ownership filings
SC 13G/A
White Lion Capital LLC
29 Mar 24
SC 13G
INTRACOASTAL CAPITAL, LLC
6 Mar 24
SC 13G
White Lion Capital LLC
12 Jan 24
SC 13G/A
White Lion Capital LLC
29 Dec 23
SC 13G
White Lion Capital LLC
30 Oct 23
4
Jeffrey John Thramann
28 Mar 23
4
Jeffrey John Thramann
21 Feb 23
SC 13G
NUVASIVE INC
3 Feb 23
4
Brent Ness
29 Dec 22
4
John Paul Lorbiecki
29 Dec 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 171.45 k | 171.45 k | 171.45 k | 171.45 k | 171.45 k | 171.45 k |
Cash burn (monthly) | 147.69 k | 207.89 k | 387.39 k | 396.05 k | 317.50 k | 337.35 k |
Cash used (since last report) | 1.01 mm | 1.42 mm | 2.64 mm | 2.70 mm | 2.17 mm | 2.30 mm |
Cash remaining | -836.04 k | -1.25 mm | -2.47 mm | -2.53 mm | -1.99 mm | -2.13 mm |
Runway (months of cash) | -5.7 | -6.0 | -6.4 | -6.4 | -6.3 | -6.3 |
Institutional ownership, Q3 2023
30.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 1 |
Closed positions | 12 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 78.60 mm |
Total shares | 2.19 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
NUVA Nuvasive | 1.13 mm | $0.00 |
Armistice Capital | 550.00 k | $41.25 mm |
Worth Venture Partners | 178.42 k | $15.84 mm |
Hudson Bay Capital Management | 160.00 k | $12.00 mm |
Captrust Financial Advisors | 78.40 k | $5.88 mm |
Clear Street | 47.66 k | $4.00 k |
Warberg Asset Management | 42.96 k | $3.22 mm |
UBS UBS Group AG - Registered Shares | 5.37 k | $403.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 23 | Jeffrey John Thramann | Other | Dispose J | No | No | 1000 | 1 | 1.00 k | 0 | |
16 Feb 23 | Jeffrey John Thramann | Buy | Acquire P | No | No | 1000 | 1 | 1.00 k | 1 | |
29 Dec 22 | Wesemann William | Stock option Common Stock | Grant | Acquire A | No | No | 2.72 | 63,000 | 171.36 k | 63,000 |
29 Dec 22 | John Paul Lorbiecki | Common Stock | Buy | Acquire P | No | No | 0.45 | 18,304.441 | 8.24 k | 22,404.411 |
29 Dec 22 | John Paul Lorbiecki | Common Stock | Buy | Acquire P | No | No | 0.43 | 4,100 | 1.76 k | 4,100 |
29 Dec 22 | Brent Ness | Common Stock | Buy | Acquire P | No | No | 0.58 | 7,711 | 4.47 k | 19,500 |
29 Dec 22 | Brent Ness | Common Stock | Buy | Acquire P | No | No | 0.51 | 8,500 | 4.34 k | 11,789 |
28 Dec 22 | Brent Ness | Common Stock | Buy | Acquire P | No | No | 0.42 | 2,289 | 961.38 | 3,289 |
News
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
2 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
2 Apr 24
Why VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
2 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
1 Apr 24
Aclarion Has Received A Notice Of Allowance For Its U.S. Patent Application 18/190,723 Titled "Magnetic Resonance Spectroscopy Pulse Sequence, Acquisition, And Processing System And Method (For Diagnosing Pain)".
1 Apr 24